The subgroup analysis revealed that the combination of nivolumab and chemotherapy exhibited lower ICERs among patients under 65 years of age, males, those with an ECOG performance-status score of 0, tumor cell PD-L1 expression ≥1%, and those who had not received previous systemic therapy for advanced urothelial carcinoma. This evidence concerns the gene CD274 and neoplasm.